In Regard to Parikh et al.

We found the phase 2 trial by Parikh et al1 on ablative, 5-fraction, stereotactic magnetic resonance –guided, on-table adaptive radiation therapy (MRgRT-SMART) intriguing. Although we acknowledge MRgRT-SMART's promise, we emphasize the need for caution in suggesting its effect on disease management unless robust evidence is provided. Despite the authors not positioning MRgRT-SMART as the primary reference technology for pancreatic cancer, there may be an overemphasis on the widespread interpretation of this evidence.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Letters to the Editor Source Type: research